[go: up one dir, main page]

NO20081816L - Farmasoytiske sammensetninger inneholdende pregabalin - Google Patents

Farmasoytiske sammensetninger inneholdende pregabalin

Info

Publication number
NO20081816L
NO20081816L NO20081816A NO20081816A NO20081816L NO 20081816 L NO20081816 L NO 20081816L NO 20081816 A NO20081816 A NO 20081816A NO 20081816 A NO20081816 A NO 20081816A NO 20081816 L NO20081816 L NO 20081816L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
compositions containing
containing pregabalin
polyvinylpyrrolidone
agents include
Prior art date
Application number
NO20081816A
Other languages
English (en)
Inventor
Howard Norman Bockbrader
Yun Hyung Cho
Steven Diaz Santiago
Majid Mahjour
Thomas Daniel Reynolds
Pushpa Ganapathi Shao
Zezhi Jesse Shao
Jiansheng Wan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081816(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20081816L publication Critical patent/NO20081816L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en faststoff farmasøytisk sammensetning inneholdende pregabalin. Sammensetningen inkluderer et matriksdannende middel og et svellingsmiddel, og er egnet for administrering oralt en gang per dag. Representative matriksdannende midler inkluderer blandinger av polyvinylacetat og polyvinylpyrrolidon, og representative svellingsmidler inkluderer kryssbundne polymerer av polyvinylpyrrolidon.
NO20081816A 2005-11-02 2008-04-14 Farmasoytiske sammensetninger inneholdende pregabalin NO20081816L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73258905P 2005-11-02 2005-11-02
PCT/IB2006/003063 WO2007052125A2 (en) 2005-11-02 2006-10-23 Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent

Publications (1)

Publication Number Publication Date
NO20081816L true NO20081816L (no) 2008-05-08

Family

ID=37965070

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081816A NO20081816L (no) 2005-11-02 2008-04-14 Farmasoytiske sammensetninger inneholdende pregabalin

Country Status (33)

Country Link
US (11) US20070269511A1 (no)
EP (1) EP1945186B1 (no)
JP (1) JP4334610B2 (no)
KR (1) KR101012533B1 (no)
CN (1) CN101330907B (no)
AP (1) AP2008004465A0 (no)
AR (1) AR058175A1 (no)
AU (1) AU2006310217B2 (no)
BR (1) BRPI0618211B8 (no)
CA (1) CA2628200C (no)
CR (1) CR9950A (no)
DK (1) DK1945186T3 (no)
DO (1) DOP2006000241A (no)
EA (1) EA012377B1 (no)
EC (1) ECSP088422A (no)
ES (1) ES2449231T3 (no)
GT (1) GT200600474A (no)
IL (1) IL190827A (no)
MA (1) MA30135B1 (no)
ME (1) ME00482B (no)
NL (1) NL2000281C2 (no)
NO (1) NO20081816L (no)
NZ (1) NZ567414A (no)
PE (1) PE20070693A1 (no)
PL (1) PL1945186T3 (no)
PT (1) PT1945186E (no)
RS (1) RS20080181A (no)
SI (1) SI1945186T1 (no)
TN (1) TNSN08194A1 (no)
TW (1) TWI330080B (no)
UY (1) UY29890A1 (no)
WO (1) WO2007052125A2 (no)
ZA (1) ZA200803115B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US8187635B2 (en) * 2007-10-16 2012-05-29 Pharmathen S.A Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
AR071274A1 (es) * 2007-12-21 2010-06-09 Synthon Bv Derivados de pregabalina , composiciones farmaceuticas que los contienen y proceso de preparacion de los mismos
US8273393B2 (en) * 2008-07-09 2012-09-25 Melaleuca, Inc. Mineral amino acid polysaccharide complex
EP2440190A1 (en) * 2009-06-12 2012-04-18 Micro Labs Limited Novel pharmaceutical compositions containing pregabalin
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
KR101317592B1 (ko) * 2009-10-28 2013-10-15 씨제이제일제당 (주) 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
CN104224737A (zh) * 2010-02-24 2014-12-24 硕腾有限责任公司 兽医组合物
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
JP5905872B2 (ja) * 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
EP2575798B1 (en) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
US20120009261A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro-retentive dosage forms
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
EP2615913A4 (en) * 2010-09-17 2014-03-19 Panacea Biotec Ltd EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
EA017542B1 (ru) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Стабильная фармацевтическая композиция, содержащая прегабалин, капсула, ее содержащая, способ получения и применение
US20140161880A1 (en) * 2011-07-26 2014-06-12 Yuhan Corporation Sustained release tablet comprising pregabalin through two-phase release-controlling system
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
CA2863371A1 (en) 2012-01-30 2013-08-08 Ranbaxy Laboratories Limited Pregabalin gr tablets
IN2014DN06966A (no) 2012-01-30 2015-04-10 Ranbaxy Lab Ltd
CN102743357A (zh) * 2012-06-26 2012-10-24 严轶东 一种普瑞巴林胃内泡腾漂浮缓释制剂及其制备方法
US9861585B2 (en) 2012-10-16 2018-01-09 Sun Pharmaceutical Industries Limited Osmotic floating tablets
IN2014MU00198A (no) * 2014-01-21 2015-08-28 Intas Pharmaceuticals Ltd
US20160338949A1 (en) 2014-01-28 2016-11-24 Sun Pharmaceutical Industries Limited Stabilized gastroretentive tablets of pregabalin
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
JP6664080B2 (ja) * 2014-10-24 2020-03-13 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． プレガバリン徐放性製剤
CN104906064B (zh) * 2015-05-15 2017-12-22 中国药科大学 一种普瑞巴林胃漂浮缓释片剂及其制备方法
US9747110B2 (en) * 2015-05-20 2017-08-29 Altera Corporation Pipelined cascaded digital signal processing structures and methods
CA2953225A1 (en) * 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
CN104840443B (zh) * 2015-05-27 2018-04-27 齐鲁制药有限公司 含活性成分普瑞巴林的药物组合物
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
WO2018015946A1 (en) * 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019142834A (ja) * 2017-07-31 2019-08-29 大原薬品工業株式会社 プレガバリン並びに好適な賦形剤を含有する固形製剤
WO2019146642A1 (ja) * 2018-01-24 2019-08-01 大原薬品工業株式会社 γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
TW202002958A (zh) * 2018-03-22 2020-01-16 日商日東電工股份有限公司 含普瑞巴林（ｐｒｅｇａｂａｌｉｎ）之組成物的製造方法及含普瑞巴林之組成物
CN111053749B (zh) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
US11938222B2 (en) 2018-06-13 2024-03-26 Beijing Tide Pharmaceutical Co., Ltd. Pregabalin sustained release composition and method for preparing the same
CN110585153A (zh) * 2018-06-13 2019-12-20 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
WO2020006372A1 (en) * 2018-06-28 2020-01-02 Mylan Inc. Pregabalin extended-release fomulations
CN109044981B (zh) * 2018-08-07 2021-02-19 广州帝奇医药技术有限公司 一种普瑞巴林胃漂浮型缓释片及其制备方法
ES2953059T3 (es) 2019-07-03 2023-11-07 Alvogen Inc Comprimidos de liberación controlada de pregabalina, método de fabricación, y método de uso de los mismos
US12012413B2 (en) * 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN110974798A (zh) * 2019-12-19 2020-04-10 江苏优仿医药科技有限公司 药物组合物、缓释片剂及其制备方法
TW202214223A (zh) * 2020-07-20 2022-04-16 大陸商四川海思科製藥有限公司 稠合三環γ-胺基酸衍生物的緩釋藥物製劑及其製備方法
TW202300138A (zh) * 2021-03-17 2023-01-01 大陸商上海博志研新藥物技術有限公司 拉考沙胺藥物組合物、其製備方法及應用
CN113577036B (zh) * 2021-05-31 2023-04-04 石药集团欧意药业有限公司 一种普瑞巴林胃漂浮缓释片及其制备方法
GB2624861A (en) * 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof
GB2639602A (en) 2024-03-19 2025-10-01 Novumgen Ltd An orodispersible tablet of pregabalin and its process of preparation
CN120324357B (zh) * 2025-06-03 2025-10-24 上海国创医药股份有限公司 一种普瑞巴林缓释组合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0124363B1 (en) 1983-05-02 1990-12-19 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5616793A (en) * 1995-06-02 1997-04-01 Warner-Lambert Company Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) * 1995-06-07 1997-06-10 Warner-Lambert Company Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US6271278B1 (en) 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
EP1003476B1 (en) 1997-08-11 2004-12-22 ALZA Corporation Prolonged release active agent dosage form adapted for gastric retention
IN186245B (no) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
CN1303991C (zh) 1998-05-15 2007-03-14 沃尼尔·朗伯公司 γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
CN100337687C (zh) 1998-05-15 2007-09-19 沃尼尔·朗伯公司 含有γ－氨基丁酸衍生物的固体组合物及其制备方法
HRP20020627B1 (hr) * 2000-01-27 2011-01-31 Warner-Lambert Company Asimetricna sinteza pregabalina
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
CA2410867C (en) 2000-06-16 2003-12-09 Claude Singer Stable gabapentin containing more than 2o ppm of chlorine ion
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
CA2356829A1 (en) * 2000-09-22 2002-03-22 Warner-Lambert Company Method for treating asthma using pregabalin
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
EP1670451A4 (en) * 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
JP2007509975A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン ギャバペンチン及びプレギャバリンの増加された吸収のための組成物及び投与形態物

Also Published As

Publication number Publication date
BRPI0618211A2 (pt) 2011-08-23
MA30135B1 (fr) 2009-01-02
KR20080059427A (ko) 2008-06-27
PT1945186E (pt) 2014-03-06
CN101330907B (zh) 2012-08-29
CR9950A (es) 2008-05-28
EP1945186B1 (en) 2014-01-22
DK1945186T3 (en) 2014-03-17
GT200600474A (es) 2007-06-08
BRPI0618211B8 (pt) 2021-05-25
CA2628200A1 (en) 2007-05-10
US20130303618A1 (en) 2013-11-14
CA2628200C (en) 2011-01-25
KR101012533B1 (ko) 2011-02-07
PE20070693A1 (es) 2007-08-11
US20150094371A1 (en) 2015-04-02
RS20080181A (sr) 2009-07-15
US20150352066A1 (en) 2015-12-10
PL1945186T3 (pl) 2014-05-30
NL2000281A1 (nl) 2007-05-03
US8945620B2 (en) 2015-02-03
ME00482B (me) 2011-10-10
UY29890A1 (es) 2007-05-31
TWI330080B (en) 2010-09-11
US20140163103A1 (en) 2014-06-12
SI1945186T1 (sl) 2014-03-31
US20120029081A1 (en) 2012-02-02
ECSP088422A (es) 2008-05-30
JP2009514847A (ja) 2009-04-09
NL2000281C2 (nl) 2007-08-07
EP1945186A2 (en) 2008-07-23
TW200803831A (en) 2008-01-16
WO2007052125A2 (en) 2007-05-10
US20070269511A1 (en) 2007-11-22
NZ567414A (en) 2011-09-30
IL190827A (en) 2012-08-30
AR058175A1 (es) 2008-01-23
TNSN08194A1 (fr) 2009-10-30
US20130102675A1 (en) 2013-04-25
US9144559B2 (en) 2015-09-29
ES2449231T3 (es) 2014-03-18
WO2007052125A3 (en) 2007-09-07
AU2006310217B2 (en) 2012-08-16
US20120232149A1 (en) 2012-09-13
IL190827A0 (en) 2008-12-29
AU2006310217A1 (en) 2007-05-10
EA200800931A1 (ru) 2008-10-30
CN101330907A (zh) 2008-12-24
US20170136125A1 (en) 2017-05-18
JP4334610B2 (ja) 2009-09-30
US20160250147A1 (en) 2016-09-01
AP2008004465A0 (en) 2008-06-30
DOP2006000241A (es) 2007-05-31
BRPI0618211B1 (pt) 2020-11-17
ZA200803115B (en) 2009-09-30
EA012377B1 (ru) 2009-10-30
US10022447B2 (en) 2018-07-17
HK1126394A1 (en) 2009-09-04
US20170348420A1 (en) 2017-12-07

Similar Documents

Publication Publication Date Title
NO20081816L (no) Farmasoytiske sammensetninger inneholdende pregabalin
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
MXPA06000407A (es) Isomero c cci-779.
BR0312347A (pt) Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
MX2009003516A (es) Formas de dosificacion solidas farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua.
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
DE602004011398D1 (de) Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK1559431T3 (da) Farmaceutisk sammensætning til thrombinpeptidderivater
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
WO2007143163A3 (en) Pharmaceutical compositions for sustained release of phenyephrine
WO2005004915A3 (en) Compositions comprising meloxicam
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
ES2305567T3 (es) Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.
CR8748A (es) Una composicion farmaceutica antimicobacteriana
DE602005027194D1 (de) Buttersäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
DE602004022515D1 (de) Fenofibrate tablett und verfahren zur herstellung
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application